(Q34463428)

2 August 2017

1 reference

title

Broad therapeutic uses of atypical antipsychotic medications (English)

1 reference

2 August 2017

P F Buckley

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

published in

Biological Psychiatry

1 reference

2 August 2017

volume

50

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

912-924

1 reference

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Comprehensive disease management for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The evolving clinical profile of atypical antipsychotic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Antipsychotic medications and the elderly: effects on cognition and implications for use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Clozapine for treatment-refractory mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Management of treatment resistance in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Effectiveness of risperidone in Huntington chorea patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The use of olanzapine for movement disorder in Huntington's disease: a first case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Quetiapine for l-dopa-induced psychosis in PD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Long-term risperidone treatment in bipolar disorder: 6-month follow up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Quetiapine fumarate (Seroquel): a new atypical antipsychotic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Three-year follow-up of older schizophrenics: Extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Pharmacologic treatment of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Remission of self-mutilation in a patient with borderline personality during risperidone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Clinical experience with quetiapine in elderly patients with psychotic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Efficacy and Tolerability of Olanzapine in Elderly Patients with Psychotic Disorders: A Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine in treatment-resistant bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Older patients with schizophrenia: challenges in the coming decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Management of psychotic, treatment-resistant depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine response in psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Behavioural problems associated with dementia: the role of newer antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Risperidone in comorbid borderline personality disorder and dysthymia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Efficacy of quetiapine in Parkinson's patients with psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901256-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01256-2

1 reference

2 August 2017

1 reference